Dyne therapeutics investors

Author: nioq

August undefined, 2024

WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Investors Dyne ... WebMar 21, 2024 · Information Security Analyst Co-Op. Dyne Therapeutics. Waltham, MA. Posted: March 16, 2024. Full-Time. Company Overview: Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary …

Dyne Therapeutics Announces Presentations on its DM1 and …

WebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual … WebMar 20, 2024 · However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release. Contacts: Investors Dyne Therapeutics … thierry sagan

Dyne Therapeutics Reports Third Quarter 2024 Financial Results …

WebFeb 27, 2024 · The 86 rating InvestorsObserver gives to Dyne Therapeutics Inc stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, DYN’s 86 overall rating means the stock scores better than 86 percent of all stocks. WebFeb 18, 2024 · Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Rating) - Oppenheimer issued their FY2024 earnings estimates for Dyne Therapeutics in a report released on Tuesday, February 14th.Oppenheimer analyst F. Brisebois expects that the company will earn ($3.17) per share for the year. Oppenheimer currently has a "Outperform" rating … saint albert the great reno nv

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus …

WebMar 20, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 ... WebMar 26, 2024 · When Dyne Therapeutics last reported its balance sheet in December 2024, it had zero debt and cash worth US$256m. In the last year, its cash burn was US$157m. Therefore, from December 2024 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces … saint albert the great school reno nvWebNov 2, 2024 · Dyne Therapeutics, Inc. WALTHAM, Mass., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life ... saint albert the great swim team

"WebNX-13. NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen … " - Dyne therapeutics investors

Dyne therapeutics investors

Dyne Therapeutics, Inc. (DYN) - Yahoo Finance

WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The … WebSep 6, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ...

Did you know?

WebJan 18, 2024 · Dyne Therapeutics (DYN-5.97%) saw its shares slump 18.1% on Tuesday. The biotech stock closed on Friday at $9.29 a share, then opened on Tuesday at $7.82, falling to a new 52-week low of $7.61 in ... WebMar 20, 2024 · The Investor Relations website contains information about Dyne Therapeutics, Inc.'s business for stockholders, potential investors, and financial … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … The Investor Relations website contains information about Dyne Therapeutics, …

WebAug 29, 2024 · Investors: Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media: Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ... WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

WebMar 23, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 … WebMar 20, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 ...

WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).

Web16 hours ago · Price To Cash Flow is a widely used stock evaluation measure. Find the latest Price To Cash Flow for Silence Therapeutics (SLN) thierry sage dijonWeb19 hours ago · As an investor, you want to buy stocks with the highest probability of success. ... Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of ... saint albinus of angersWebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... thierry sagnierWebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … thierry sageaux freeWebDyne Therapeutics General Information. Description. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. thierry sagardoytho avocatWebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. thierry said managerWeb10 rows · Dyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was ... thierry sagory planguenoual